CollaborationLimmaTech Biologics acquires licence optio...Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVaccs preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success. more ➔
Novel FoodFrench parliamentarians against cell-based...The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France. more ➔
FinancingVandria SA bags CHF18m in Series A financi...Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318. more ➔
financingAntabio SAS raises €25 m in Series B fin... Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors. more ➔
BioeoconomyProduction process for cell-based coffee p...Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production. more ➔
NGTGermany blocks deregulation of NGT breedsAt the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commissions draft regulation on new genomic technique … more ➔
financingCathera SA closes Series B round at €42mSorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials. more ➔
FinancingUK publishes £2bn vision for engineering... On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology. more ➔
Lyme vaccineValnevas Lyme vaccine trial completes recr...Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled. more ➔
cancerUnveiling prostate cancer’s Achilles...Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets. more ➔